Ads
related to: 10 point drop in egfr positive breast cancer
Search results
Results From The WOW.Com Content Network
An example of a pure EGFR inhibitor is gefitinib, which has been used in phase II trials to evaluate its addition to tamoxifen in patients with HR-positive advanced breast cancer. [ 22 ] The PI3K-Akt-mTOR signaling pathway and crosstalk with the ER signaling pathway is thought to be involved in the development of resistance to endocrine therapy.
The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. [6]
HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. But contrary to other members of the ERBB family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer. [8]
Epidermal growth factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor, EGFR. Human EGF is 6-kDa [5] and has 53 amino acid residues and three intramolecular disulfide bonds.
The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. This test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor -positive (ER+) invasive breast cancer who will be treated with hormone therapy .
Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances ...
Ads
related to: 10 point drop in egfr positive breast cancer